Oncomatryx Biopharma SL

NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approval from China National Medical Products Administration (NMPA) recently. OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type II serine protease highly focal expressed in cancer-associated fibroblasts (CAF) surrounding the tumor cells and microvasculature. InxMed' studies and other publications consistently show that FAP-expressing CAFs play important roles in tumor drug resistance. InxMed has explored and demonstrated the potential antitumoral efficacy of FAPα targeting treatment for various caner types, especially those with high incidence in Chinese population e.g., gastric cancer, esophagus cancer, etc. The company reached a collaboration with Oncomatryx, a company developing novel drugs targeting the tumor microenvironment, to co-research and develop OMTX705 preclinically and clinically, and own the commercialization rights of OMTX705 in Asia. InxMed has been developing novel ADC drugs for hard-to-treat solid tumors since 2019. The company has demonstrated promising synergistic anticancer effects of combination therapy comprising various ADC drugs and its pivotal-trial stage drug IN10018 (Ifebemtinib), a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in animal models. InxMed is actively exploring and maximizing the potential of this treatment regimen through its own synergistic pipelines and partnering. About InxMed InxMed is a clinical-stage biotech company established in the end of 2018. The company dedicates on developing innovative therapies targeting stroma microenvironment and solid tumor resistance and metastasis, especially new drug development on anti PD-1/PD-L1 treatment drug resistance. InxMed committees to building an efficient engine for clinical translational science and proof of concept platform driven by in-depth understanding of disease biology and is committed to becoming a global leader in revolutionary cancer therapies. InxMed has established translational medicine and clinical teams at Nanjing， Shanghai and Beijing in China, and hubs in the United States, Canada and Australia. Through independent discovery research and development, and collaborative research and development, InxMed has built a unique and synergistic global pipeline. InxMed has completed several rounds of financing totaling more than 100 million US dollars. Its first novel drug, IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), received Fast-track Designation from the U.S. Food and Drug Administration and Breakthrough Therapy Designation from the China National Medical Products Administration. The pivotal clinical trial supporting market approval is ongoing. SOURCE InxMed Co., Ltd

ZAMUDIO, Spain--(BUSINESS WIRE)-- Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates the cytolysin toxic payload developed by Tube, is a first-in-class antibody-drug conjugate targeting cancer-associated fibroblasts. OMTX705 has shown complete tumor regression in many PDx and syngeneic murine models, as well as an unbeatable safety pro rats and monkeys. A FIH multiple expansion cohort clinical trial targeting metastatic solid tumors is ongoing in seven hospitals in Spain and USA. Oncomatryx now owns the comprehensive portfolio of cytolysins synthesized by Tube and the cutting-edge technology developed in its laboratories. Led by Dr. Wolfgang Richter, the Austrian company has more than 15 years of experience and has positioned itself as a top-level benchmark in the generation of novel ADC payloads. This significant step forward in Oncomatryx internationalization strategy will also enhance its chemistry department thanks to the incorporation of Dr. Richter, who will drive the company’s efforts to continue developing novel drugs that attack the tumor microenvironment. According to Laureano Simon, founder of Oncomatryx, "This strategic agreement is a significant milestone for Oncomatryx. It consolidates our technological portfolio and our commitment to target the microenvironment of the most invasive tumors. In addition, bringing Dr. Richter's knowledge and experience into our team will open up even more possibilities in the design and development of novel ADCs." It is worth noting that over the past 10 years, Oncomatryx has been involved in the development of innovative medicines in collaboration with prestigious universities, hospitals, and research centers in Europe and USA, such as the University of Stuttgart, the University of Torino, CIC-Biogune, the National Center for Oncological Research, Onkologikoa, Harvard University and the MD Anderson Cancer Center, among others. About Oncomatryx Oncomatryx is a pioneering global bio-pharmaceutical company that targets the microenvironment of the most invasive tumors through its next-generation precision ADCs, bispecific antibodies and small molecules. Located in the Bizkaia Technology Park, the company has discovered novel mechanisms and proteins in the tumor microenvironment that facilitate tumor invasiveness, immunosuppression, drug resistance and metastasis. Oncomatryx is investing 100 million euros to develop its pioneering tumor-microenvironment pipeline into clinical trials against these most invasive solid tumors.